Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) will issue its quarterly earnings data after the market closes on Thursday, August 1st. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.
Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02. On average, analysts expect Oncolytics Biotech to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Oncolytics Biotech Trading Down 2.0 %
Shares of ONCY stock traded down $0.02 during trading hours on Tuesday, reaching $1.03. 30,908 shares of the company’s stock were exchanged, compared to its average volume of 283,330. Oncolytics Biotech has a 1 year low of $0.88 and a 1 year high of $2.62. The stock has a market cap of $78.60 million, a PE ratio of -3.50 and a beta of 1.91. The stock’s fifty day moving average price is $1.04 and its two-hundred day moving average price is $1.08.
Analyst Ratings Changes
View Our Latest Analysis on Oncolytics Biotech
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
- Five stocks we like better than Oncolytics Biotech
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- Market Cap Calculator: How to Calculate Market Cap
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Aerospace Stock Fires Up a Solid EPS Beat and Raises Guidance
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.